Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Eli Lilly (LLY) sell-off 'overdone' on CVS move on Wegovy - Leerink
May 2, 2025 9:33 AM EDTLeerink Partners analyst David Risinger reiterated an Outperform rating and $944.00 price target on Eli Lilly (NYSE: LLY), saying yesterday's 12% pullback creates a buying opportunity.
The analyst commented, "Despite LLY downplaying CVS Caremarks action favoring Wegovy over Zepbound, LLY shares declined 11.7% yesterday.... More
